Associated Papers
Enzymatic and genetic evaluation of butyrylcholinesterase in male infertility.
Habib R et al.
F&s Science, 2026
Genetic and functional dynamics of Butyrylcholinesterase in Alzheimer's disease: From mechanisms to clinical relevance.
Prešern U et al.
Chemico-biological Interactions, 2026
Discovery of a new function of human butyrylcholinesterase and the catalytic activity of its natural variants toward homocysteine thiolactone hydrolysis.
Chen X et al.
Chemico-biological Interactions, 2025
Hereditary Pseudocholinesterase Deficiency and Succinylcholine: Historical Perspective, Therapeutic Implications, and Future Considerations.
Nguyen JQ et al.
Pharmacotherapy, 2025
Variants in Neurotransmitter-Related Genes Are Associated with Alzheimer's Disease Risk and Cognitive Functioning but Not Short-Term Treatment Response.
Zúñiga-Santamaría T et al.
Neurology International, 2025
Hereditary pseudocholinesterase deficiency in a 4-year-old girl: a case report.
Schulze-Berge J et al.
Journal of Medical Case Reports, 2025
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Kuras M et al.
Cancers, 2025
Uncovering dark mass in population proteomics: Pan-analysis of single amino acid polymorphism relevant to cognition and aging.
Gao X et al.
Cell Genomics, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.
Maggo S et al.
Frontiers in Genetics, 2025
A novel BCHE frameshift mutation in a Chinese woman with butyrylcholinesterase deficiency: A case report and literature review.
Zeng J et al.
Medicine, 2024
Emerging significance of butyrylcholinesterase.
Sridhar GR et al.
World Journal of Experimental Medicine, 2024
The Association of Selected GWAS Reported AD Risk Loci with CSF Biomarker Levels and Cognitive Decline in Slovenian Patients.
Vogrinc D et al.
International Journal of Molecular Sciences, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Genetic Association of Butyrylcholinesterase with Major Depressive Disorder.
Awan S et al.
Biochemical Genetics, 2022
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
Characterization of four BCHE mutations associated with prolonged effect of suxamethonium.
Brazzolotto X et al.
The Pharmacogenomics Journal, 2021
Phenotype and genotype characteristics of 58 patients showing a prolonged effect of succinylcholine: A four-year experience.
Millet C et al.
Anaesthesia, Critical Care & Pain Medicine, 2021
Butyryl-cholinesterase deficiency: A case report of delayed recovery after general anaesthesia.
Al-Emam A
Toxicology Reports, 2021
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Hemasphere, 2020
Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine.
Zhu GD et al.
Pharmacogenomics and Personalized Medicine, 2020
Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?
Jasiecki J et al.
Biomolecules, 2019
Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity.
Jasiecki J et al.
Chemico-biological Interactions, 2019
Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Jasiecki J et al.
Scientific Reports, 2019
Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.
Munir S et al.
Journal of Molecular Neuroscience : Mn, 2019
Molecular characterization and polymorphisms of butyrylcholinesterase in cynomolgus macaques.
Uno Y et al.
Journal of Medical Primatology, 2018
A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report.
Yu R et al.
Bmc Medical Genetics, 2018
Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency.
Levano S et al.
Neuromuscular Disorders : Nmd, 2017
Activity and polymorphisms of butyrylcholinesterase in a Polish population.
Jasiecki J et al.
Chemico-biological Interactions, 2016
Naturally Occurring Genetic Variants of Human Acetylcholinesterase and Butyrylcholinesterase and Their Potential Impact on the Risk of Toxicity from Cholinesterase Inhibitors.
Lockridge O et al.
Chemical Research in Toxicology, 2016
Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene.
Wichmann S et al.
Pharmacogenetics and Genomics, 2016
The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.
Lim CH et al.
Oncotarget, 2016
[Prolonged neuromuscular block in a patient with butyrylcholinesterase deficiency].
Mabboux I et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie, 2016
The rs1803274 polymorphism of the BCHE gene is associated with an increased risk of coronary in-stent restenosis.
Pleva L et al.
Bmc Cardiovascular Disorders, 2015
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Delacour H et al.
Plos One, 2014
Prolonged Paralysis After Electroconvulsive Therapy Due to Butyrylcholinesterase Gene Mutation.
Maxwell J et al.
Journal of Clinical Psychopharmacology, 0